Chemical and Pharmaceutical Bulletin
Online ISSN : 1347-5223
Print ISSN : 0009-2363
ISSN-L : 0009-2363
71 巻, 9 号
選択された号の論文の12件中1~12を表示しています
Communication to the Editor
Regular Articles
  • Ji-hyun Kang, Seung-Dong Yoo, Ki-Hun Han, So-Jeong Jeong, Hyo-Jung Lee ...
    2023 年 71 巻 9 号 p. 678-686
    発行日: 2023/09/01
    公開日: 2023/09/01
    [早期公開] 公開日: 2023/06/23
    ジャーナル フリー HTML

    Pirfenidone (PRF) is an anti-fibrotic agent that has been approved by the Food and Drug Administration (FDA) for the treatment of mild to moderate idiopathic pulmonary fibrosis. However, the current oral administration dosing regimen of PRF is complex and requires high doses. Patients are instructed to take PRF three times daily, with each dose consisting of up to three capsules or tablets (600 mg/d or 1.8 g/d of PRF) taken with food. To improve the dosing regimen, efforts are being made to develop an extended-release tablet with a zero-order release pattern. In this study, two types of extended-release matrix tablets were compared: non-channeled extended-release matrix tablets (NChMT) and channeled extended-release matrix tablets (ChMT). In vitro release tests, swelling and erosion index, rheology studies, and X-ray microcomputed tomography (XRCT), were conducted. The results indicated that ChMT maintained a zero-order release pattern with a constant release rate, while NChMT exhibited a decreased release rate in the latter half of the dissolution. ChMT exhibited accelerated swelling and erosion compared to other formulations, and this was made possible by the presence of channels within the tablet. These channels allowed for thorough wetting and swelling throughout the entire depth of the tablet. The formation of channels was confirmed through XRCT images. In conclusion, the presence of channels in ChMT tablets increased the rate of swelling and erosion, resulting in a zero-order release pattern. This development offers the potential to improve the dosage of PRF and reduce its associated side effects.

  • Shohei Nakamura, Nanami Ito, Ayumi Sakurada, Takatoshi Sakamoto
    2023 年 71 巻 9 号 p. 687-694
    発行日: 2023/09/01
    公開日: 2023/09/01
    ジャーナル フリー HTML

    Lactose is an excipient used extensively for bulking, diluting, and molding active pharmaceutical ingredients in tablet manufacturing. Particularly, granulated lactose (GL) intended for direct powder compression has distinct properties due to differences in manufacturing methods. It contributes to handling blended powders for tableting and tablet quality. In this study, we aimed to compare the functions of different forms of GL added as excipients during direct powder compression on the tablet properties and the effect of magnesium stearate (Mg-S) used as a lubricant on each type of GL. Different GL types obtained using different manufacturing methods (agitated granulation, GL-AG; spray-dried granulation, GL-SD; fluidized bed granulation, GL-FB) were blended with maize starch, low-substituted hydroxypropyl cellulose, and paracetamol in a V-type blender for 10 min. Mg-S was added at varying amounts (0.1, 1.0, and 2.0%) and blending times (5, 10, and 30 min) for the nine types of blended powders for tableting formulation. The powders were tableted, and the tablets were evaluated for weight and drug loading variations, tensile strength, friability, and disintegration time. When tablets with the same blending conditions were compared, the tensile strength and disintegration time were in the order of GL-FB > GL-SD > GL-AG. For each GL, we analyzed the effects of changes in the added amount of Mg-S and blending time using contour plots, evaluated the effects of blending conditions on tablet properties, and determined the target tablet properties. We investigated the optimization of the lubricant blending conditions to obtain suitable tablets.

    Editor's pick

    This study evaluated the effects of different forms of granulated lactose (GL) on the physical properties of tablets and the effect of magnesium stearate on each type of GL. The different forms of GL such as agitated granulation (GL-AG), spray-dried granulation (GL-SD), and fluidized bed granulation (GL-FB) were added as excipients during direct powder compression. When tablets with the same blending conditions were compared, the tensile strength and disintegration time followed the order as GL-FB > GL-SD > GL-AG. The authors presented selection criteria for the suitability of different forms of GL during tableting by examining the relevance between the type of GL and properties of the tablets produced.

  • Kakeru Matsukuma, Masanori Tayu, Yuriko Yashiro, Tomohisa Yamaguchi, S ...
    2023 年 71 巻 9 号 p. 695-700
    発行日: 2023/09/01
    公開日: 2023/09/01
    ジャーナル フリー HTML
    電子付録

    Sulfides and their derivatives are among the most important class of reagent in synthetic chemistry. Despite the importance of such compounds, the use of sulfide radical cations in synthetic chemistry is underdeveloped. To address this issue, herein, we describe alkene chlorotrifluoromethylation reactions promoted by photoredox/sulfide dual catalysis systems, which involves sulfide radical cations generated through the oxidation of sulfides by a photoredox catalyst. The high functional group tolerance of this chemistry was demonstrated using natural products and drug molecules as substrate alkenes.

  • Shota Kawai, Shunsuke Takashima, Masafumi Ando, Sayaka Shintaku, Shige ...
    2023 年 71 巻 9 号 p. 701-716
    発行日: 2023/09/01
    公開日: 2023/09/01
    ジャーナル フリー HTML

    The readthrough mechanism, which skips the premature termination codon and restores the biosynthesis of the defective enzyme, is an emerging therapeutic tactic for nonsense mutation-related diseases, such as Hurler syndrome, a type of mucopolysaccharidosis. In the present study, novel triaryl derivatives were synthesized and their readthrough-inducing activities were evaluated by a luciferase reporter assay with a partial α-L-iduronidase (IDUA) DNA sequence containing the Q70X nonsense mutation found in Hurler syndrome and by measuring the enzyme activity of IDUA knockout cells transfected with the mutant IDUA gene. KY-516, a representative compound in which the meta position carboxyl group of the left ring of the clinically used ataluren was converted to the para position sulfamoylamino group, the central ring to triazole, and the right ring to cyanobenzene, exhibited the most potent readthrough-inducing activity in the Q70X/luciferase reporter assay. In Q70X mutant IDUA transgenic cells, KY-516 significantly increased enzyme activity at 0.1 µM. After the oral administration of KY-516 (10 mg/kg), the highest plasma concentration of KY-516 was above 5 µM in rats. These results indicate that KY-516, a novel triaryl derivative, exhibits potent readthrough-inducing activity and has potential as a therapeutic agent for Hurler syndrome.

    Editor's pick

    Readthrough therapy, which restores the biosynthesis of full-length proteins by incorporating an amino acid at a premature termination codon and allowing translation to continue, has recently been actively investigated for its application to nonsense mutation-related diseases. In this article, triaryl derivatives were synthesized and evaluated for the development of novel readthrough agents to treat mucopolysaccharidosis type I, which is caused by nonsense mutations in the IDUA gene. KY-516, a representative compound, exhibited excellent readthrough-inducing activity in the luciferase assay and significantly increased enzyme activity in mutant IDUA transgenic cells.

  • Fumihiro Kawagoe, Sayuri Mototani, Kaori Yasuda, Hiroki Mano, Akiko Ta ...
    2023 年 71 巻 9 号 p. 717-723
    発行日: 2023/09/01
    公開日: 2023/09/01
    [早期公開] 公開日: 2023/07/08
    ジャーナル フリー HTML
    電子付録

    As an extension of our research on providing a chemical library of side-chain fluorinated vitamin D3 analogues, we newly designed and synthesized 26,27-difluoro-25-hydroxyvitamin D3 (1) and 26,26,27,27-tetrafluoro-25-hydroxyvitamin D3 (2) using a convergent method applying the Wittig–Horner coupling reaction between CD-ring ketones (13, 14) and A-ring phosphine oxide (5). The basic biological activities of analogues, 1, 2, and 26,26,26,27,27,27-hexafluoro-25-hydroxyvitamin D3 [HF-25(OH)D3] were examined. Although the tetrafluorinated new compound 2 exhibited higher binding affinity for vitamin D receptor (VDR) and resistance to CYP24A1-dependent metabolism compared with the difluorinated 1 and its non-fluorinated counterpart 25-hydroxyvitamin D3 [25(OH)D3], HF-25(OH)D3 showed the highest activity among these compounds. Osteocalcin promoter transactivation activity of these fluorinated analogues was tested, and it decreased in the order of HF-25(OH)D3, 2, 1, and 25(OH)D3 in which HF-25(OH)D3 showed 19-times greater activity than the natural 25(OH)D3.

    Editor's pick

    In this Article, the authors investigated the effects of fluorine atoms introduced to the terminal positions of the side chain (26 and 27-positions) of 25-hydroxyvitamin D3 (25(OH)D3) on vitamin D receptor (VDR) binding affinity, osteocalcin promoter transactivation activity, and levels of resistance against CYP24A1-dependant metabolism. They revealed that these biological activities were enhanced in the order of 26,27-difluoro, 26,26,27,27-tetrafluoro, and 26,26,26,27,27,27-hexafluoro-25(OH)D3. Introduction of fluorines at these positions lead to improvements on functions as VDR-ligands and biological activity. With regard to the VDR binding affinity, the authors considered those potency improvements might be attributed to the increased acidity of the 25-OH group.

Notes
feedback
Top